Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic

Angela Boudreau

Abstract


The oncology clinic is changing, with an increasing number of cancer therapies becoming available as formulations for subcutaneous (SC) injection. Using targeted therapies, such as alemtuzumab, bortezomib, rituximab or trastuzumab, via SC injection can be advantageous for patients, healthcare professionals, and healthcare systems. However, their use can also present challenges, and nurses have a unique opportunity to positively influence the integration of SC agents in the clinic. This article summarizes practical suggestions for optimal administration of SC targeted therapies, and provides pragmatic considerations for managing the change process related to their adoption. 


Full Text:

PDF

References


Barrow, J. M., & Toney-Butler, T. J. (2019). Change Management. In StatPearls. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK459380/

BC Cancer Agency. (2015). BC Cancer Agency Drug Manual: alemtuzumab. Retrieved from http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Alemtuzumab_Monograph_1May2015.pdf

Carlson, J., Cox, K., Bedwell, K., & Ku, M. (2015). Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. International Journal of Nursing Practice, 21(S3), 1–13. https://doi.org/10.1111/ijn.12413

Davidson, J. (2015). What’s all the buzz about change management? Healthcare Management Forum, 28(3), 118–120. https://doi.org/10.1177/0840470415570174

Davies, A., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P., Rule, S., … Badoux, X. (2017). Subcutaneous Rituximab for the treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy, 34(10), 2210–2231. https://doi.org/10.1007/s12325-017-0610-z

De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016). A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer. Cancer Medicine, 5(3), 389–397. https://doi.org/10.1002/cam4.573

Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., … Poirier, B. (2019). A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Current Oncology, 26(1), e70–e80. https://doi.org/10.3747/co.26.4220

Haller, M. F. (2007). Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharmaceutical Technology, 31(10). Retrieved from http://www.pharmtech.com/converting-intravenous-dosing-subcutaneous-dosing-recombinant-human-hyaluronidase

Hoffmann-La Roche Ltd. (2018a). HERCEPTIN SC (trastuzumab) Product Monograph. Retrieved from https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97124

Hoffmann-La Roche Ltd. (2018b). RITUXAN SC (rituximab) Product Monograph. Retrieved from https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94441

Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014). Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Und Frauenheilkunde, 74(4), 343–349. https://doi.org/10.1055/s-0034-1368173

Janssen Inc. (2018). VELCADE (bortezomib) Product Monograph. Retrieved from https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74782

Kurtin, S., Knop, C. S., & Milliron, T. (2012). Subcutaneous administration of Bortezomib: Strategies to reduce injection site reactions. Journal of the Advanced Practitioner in Oncology, 3(6), 406–410.

Leveque, D. (2014). Subcutaneous administration of anticancer agents. Anticancer Research, 34(4), 1579–1586.

Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., … Österborg, A. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100(3), 768–773. https://doi.org/10.1182/blood-2002-01-0159

MacDonald, D., Crosbie, T., Christofides, A., Assaily, W., & Wiernikowski, J. (2017). A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Current Oncology, 24(1), 33–39. https://doi.org/10.3747/co.24.3470

Martin, J. (2013). The subcutaneous administration of Bortezomib Practice Guideline Capstone Project (Regis University). Retrieved from https://epublications.regis.edu/theses/202

Martin, J. R., Beegle, N. L., Zhu, Y., & Hanisch, E. M. (2015). Subcutaneous administration of Bortezomib: A pilot survey of oncology nurses. Journal of the Advanced Practitioner in Oncology, 6(4), 308–318.

Möbus, V., Mahlberg, R., Janni, W., Tomé, O., Marmé, F., Forstbauer, H., … Loibl, S. (2018). Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Research, 78(4 Suppl.), P5-20-09–P5-20–09. https://doi.org/10.1158/1538-7445.SABCS17-P5-20-09

Pivot, X., Verma, S., Fallowfield, L., Müller, V., Lichinitser, M., Jenkins, V., … Gligorov, J. (2017). Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. European Journal of Cancer, 86, 82–90. https://doi.org/10.1016/j.ejca.2017.08.019

Platzbecker, U., Aul, C., Ehninger, G., & Giagounidis, A. (2010). Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Annals of Hematology, 89(4), 427–428. https://doi.org/10.1007/s00277-009-0824-5

Sanofi Genzyme. (2018). MABCAMPATH (alemtuzumab) Product Monograph. Retrieved from https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77636

Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Schlenk, R. F., Groner, S., … Döhner, H. (2009). Subcutaneous Alemtuzumab in Fludarabine-Refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H Ssudy of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27(24), 3994–4001. https://doi.org/10.1200/JCO.2008.21.1128


Refbacks

  • There are currently no refbacks.